SUDEEPPHRM Share Price | Sudeep Pharma Ltd Stock Analysis & Recommendation

Q: Why is Sudeep Pharma Ltd falling/rising?

As of 01-Sep, Sudeep Pharma Ltd's stock price is rising, currently at 1,223.70, reflecting a change of 13.35 (1.1%) upward. The stock has shown significant performance over various periods, with a 1-week return of +8.37% and a remarkable 1-month return of +39.15%, both outperforming the Sensex, which has seen declines of -0.92% and -1.47%, respectively. Year-to-date, the stock has increased by +103.12%, while the Sensex has decreased by -9.71%.Today's trading activity indicates strong momentum, as the stock has been gaining for the last five days, with an overall increase of 8.37% during this period. Although it opened with a loss of -2.88%, it quickly rebounded, reaching an intraday high of Rs 1264.25, which is also a new 52-week and all-time high for the stock. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend.Additionally, there has been a notable increase in investor participation, with delivery volume rising by 147.74% compared to the 5-day average, suggesting growing interest and confidence among investors. The company's financial health is also a positive factor, as it maintains a low Debt to EBITDA ratio of 0.68 times, indicating a strong ability to service its debt. Overall, these factors contribute to the rising stock price of Sudeep Pharma Ltd.

Q: What does Sudeep Pharma do?

Overview: Sudeep Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.History: Sudeep Pharma Limited was incorporated as 'Sudeep Pharma Private Limited' on December 21, 1989, and later converted into a public limited company, changing its name to 'Sudeep Pharma Limited' on October 21, 2024. The most recent quarterly results reported net sales and net profit for June 2026.Financial Snapshot: Net Sales: 158 Cr (Quarterly Results - Jun 2026) Net Profit: 41 Cr (Quarterly Results - Jun 2026) Market cap: INR 13,040 Cr (Small Cap)Key Metrics: P/E: 75.00 Industry P/E: 37 Dividend Yield: 0.13% Debt Equity: 0.04 Return on Equity: 19.57% Price to Book: 14.74Contact Details: Registrar Address: Not available. Phone: N/A Email: N/A Website: N/A

Q: Who are the peers of the Sudeep Pharma?

Peers: The peers of Sudeep Pharma are Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Jubilant Pharmo, Akums Drugs, Viyash Scientifi, Blue Jet Health, and Sanofi Consumer.Quality Snapshot: Excellent management risk is observed at Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Blue Jet Health, and Sanofi Consumer, while Average management risk is found at Jubilant Pharmo and Akums Drugs. Below Average management risk is noted for Viyash Scientifi. All peers exhibit Below Average growth except for Viyash Scientifi, which has Good growth, while Akums Drugs shows Average growth. Excellent capital structure is present in Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Akums Drugs, Blue Jet Health, and Sanofi Consumer, while Average capital structure is found at Jubilant Pharmo and Below Average at Viyash Scientifi.Return Snapshot: Marksans Pharma has the highest 1-year return at 91.38%, while Concord Biotech has the lowest at -13.77%. Sudeep Pharma's 1-year return is not available for comparison. Additionally, Natco Pharma, Jubilant Pharmo, Blue Jet Health, and Sanofi Consumer all have negative six-month returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.52 lacs (55.31%) Volume

Shareholding (Jun 2026)

FII

1.81%

Held by 17 FIIs

DII

15.64%

Held by 9 DIIs

Promoter

76.15%

Why is Sudeep Pharma Ltd falling/rising?

02-Sep-2026

As of 01-Sep, Sudeep Pharma Ltd's stock price is 1,223.70, reflecting a 1.1% increase. The stock has shown strong performance with significant returns over various periods, outperforming the Sensex, and demonstrating strong investor interest and financial health.

View full answer

What does Sudeep Pharma do?

01-Sep-2026

Sudeep Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹158 Cr and a net profit of ₹41 Cr for June 2026. It has a market cap of ₹13,040 Cr, a P/E ratio of 75.00, and a return on equity of 19.57%.

View full answer

Who are the peers of the Sudeep Pharma?

01-Sep-2026

Sudeep Pharma's peers include Alembic Pharma, Concord Biotech, Natco Pharma, Marksans Pharma, Jubilant Pharmo, Akums Drugs, Viyash Scientifi, Blue Jet Health, and Sanofi Consumer. Most peers show below-average growth and varying management risks, with Marksans Pharma leading in 1-year returns at 91.38%.

View full answer

How big is Sudeep Pharma?

01-Sep-2026

As of 31st August, Sudeep Pharma Ltd has a market capitalization of 13,040.00 Cr, with recent net sales of 675.62 Cr and a net profit of 182.64 Cr.

View full answer

Which are the latest news on Sudeep Pharma?

01-Sep-2026

Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 1264.25
Sudeep Pharma Ltd Hits All-Time High of Rs 1,257.25 as Momentum Builds Across Timeframes

Are Sudeep Pharma Ltd latest results good or bad?

05-Aug-2026

Sudeep Pharma Ltd's latest results show strong year-on-year growth with a 31.61% increase in net profit and a 26.70% rise in revenue, but there are concerns due to a 17.04% decline in net profit from the previous quarter and slight contraction in operating margin, indicating potential challenges ahead. Investors should monitor these trends closely.

View full answer

Should I buy, sell or hold Sudeep Pharma Ltd?

05-Aug-2026

When is the next results date for Sudeep Pharma Ltd?

28-Jul-2026

The next results date for Sudeep Pharma Ltd is August 4, 2026.

View full answer

Compare Sudeep Pharma with Similar Stocks

Jubilant Pharmo Corona Remedies Marksans Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 0%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.68 times

Poor long term growth as Operating profit has grown by an annual rate 0% of over the last 5 years

Flat results in Jun 26

With ROE of 19.6, it has a Very Expensive valuation with a 15.6 Price to Book Value

Falling Participation by Institutional Investors

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 14,107 Cr (Small Cap)

P/E

76.00

Industry P/E

Dividend Yield

0.12%

Debt Equity

0.04

Return on Equity

19.57%

Price to Book

15.48

Revenue and Profits:

Net Sales:

158 Cr

(Quarterly Results - Jun 2026)

Net Profit:

41 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0.12%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

56.29%

0.20%

56.49%

6 Months

91.4%

0.26%

91.66%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Latest dividend: 1.5000000000000002 per share ex-dividend date: Jul-23-2026

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 1264.25

After a steady five-day ascent delivering over 10.6% returns, Sudeep Pharma Ltd surged to a fresh 52-week and all-time high of Rs 1264.25 on 1 Sep 2026, outpacing its sector by 3.71% despite a broader market retreat. This milestone caps a remarkable journey from its 52-week low of Rs 524.95, underscoring the stock’s robust price momentum and technical alignment.

Read full news article

Sudeep Pharma Ltd Hits All-Time High of Rs 1,257.25 as Momentum Builds Across Timeframes

After a modest gap down at the open, Sudeep Pharma Ltd staged a strong recovery to close at a fresh all-time high of Rs 1,257.25 on 1 Sep 2026, extending its winning streak to five consecutive sessions with a cumulative gain of 10.88% during this period.

Read full news article

Sudeep Pharma Ltd Locks at Upper Circuit With 5.0% Gain — Buyers Queue, Sellers Absent

At Rs 1209.7, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sudeep Pharma Ltd locked at its upper circuit of 5.0% on 31 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

11-Aug-2026 | Source : BSE

Submission of Earnings Call Transcript for the call held on 05.08.2026

General Update

06-Aug-2026 | Source : BSE

General Update

Shareholder Meeting / Postal Ballot-Scrutinizers Report

05-Aug-2026 | Source : BSE

Submission of E-voting and Scrutinizers Report for the 37th Annual General Meeting held on 04.08.2026

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Sudeep Pharma Ltd has declared 150% dividend, ex-date: 23 Jul 26

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

33.98

Debt to EBITDA (avg)

0.72

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.65

Tax Ratio

23.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

17.46%

ROCE (avg)

24.88%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

15.65

EV to EBIT

66.91

EV to EBITDA

62.45

EV to Capital Employed

15.08

EV to Sales

21.58

PEG Ratio

Dividend Yield

0.12%

ROCE (Latest)

22.53%

ROE (Latest)

19.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (5.47%)

FIIs

Held by 17 FIIs (1.81%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (2.95%)

Individual Investors Holdings

4.89%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.68",
          "val2": "80.17",
          "chgp": "31.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.19",
          "val2": "28.89",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.76",
          "val2": "1.97",
          "chgp": "-10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "33.83",
          "val2": "25.77",
          "chgp": "31.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.08%",
          "val2": "36.04%",
          "chgp": "1.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "168.06",
          "val2": "168.40",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.27",
          "val2": "60.03",
          "chgp": "2.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.47",
          "val2": "1.99",
          "chgp": "74.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "54.95",
          "val2": "41.98",
          "chgp": "30.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.46%",
          "val2": "35.65%",
          "chgp": "0.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "258.34",
          "val2": "251.88",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.88",
          "val2": "86.49",
          "chgp": "5.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "3.24",
          "chgp": "26.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "81.82",
          "val2": "62.61",
          "chgp": "30.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "35.18%",
          "val2": "34.34%",
          "chgp": "0.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

105.68

80.17

31.82%

Operating Profit (PBDIT) excl Other Income

39.19

28.89

35.65%

Interest

1.76

1.97

-10.66%

Exceptional Items

0.00

Standalone Net Profit

33.83

25.77

31.28%

Operating Profit Margin (Excl OI)

37.08%

36.04%

1.04%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026

Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

168.06

168.40

-0.20%

Operating Profit (PBDIT) excl Other Income

61.27

60.03

2.07%

Interest

3.47

1.99

74.37%

Exceptional Items

0.00

Standalone Net Profit

54.95

41.98

30.90%

Operating Profit Margin (Excl OI)

36.46%

35.65%

0.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

258.34

251.88

2.56%

Operating Profit (PBDIT) excl Other Income

90.88

86.49

5.08%

Interest

4.10

3.24

26.54%

Exceptional Items

0.00

Standalone Net Profit

81.82

62.61

30.68%

Operating Profit Margin (Excl OI)

35.18%

34.34%

0.84%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

642.26

502.00

27.94%

Operating Profit (PBDIT) excl Other Income

221.91

189.95

16.83%

Interest

7.60

5.85

29.91%

Exceptional Items

0.00

Consolidate Net Profit

172.89

138.73

24.62%

Operating Profit Margin (Excl OI)

34.55%

37.84%

-3.29%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

All Annual Results

Company CV

About Sudeep Pharma Ltd

Sudeep Pharma Ltd

Small Cap

Pharmaceuticals & Biotechnology

Sudeep Pharma Limited was incorporated as `Sudeep Pharma Private Limited' as a private limited company dated December 21, 1989, with the Registrar of Companies, Ahmedabad. Thereafter, Company was subsequently converted into a public limited company and the name of the Company was changed to `Sudeep Pharma Limited' pursuant to fresh certificate of incorporation dated October 21, 2024, issued by the Central Processing Centre.

Company Coordinates

No Company Details Available